| POI | Primary ovarian insufficiency |
| ASCO | American Society of Clinical Oncology |
| HFEA | Human Fertilization and Embryology Authority |
| ASRM | American Society for Reproductive Medicine |
| CMF | Cyclophosphamide, methotrexate, fluorouracil |
| CEF | Cyclophosphamide, epirubicin, fluorouracil |
| CAF | Cyclophosphamide, doxorubicin (Adriamycin), fluorouracil |
| AC | Doxorubicin (Adriamycin), cyclophosphamide |
| ABVD | doxorubicin/bleomycin/vinblastin/dacarbazine |
| CHOP | cyclophosphamide/doxorubicin/vincristine/prednisone |
| CVP | cyclophosphamide/vincristine/prednisone |
| AML | Acute myeloid leukemia |
| ALL | Acute lymphoblastic leukemia |
| DSB | Double-strand break |
| PI3K/AKT/FOXO3a | Phosphoinositide 3-kinase/protein kinase B/forkhead box protein O3a |
| GnRH | Gonadotropin-releasing hormone |
| OSC | Ovarian stem cell |
| IVF | In vitro fertilization |
| UK | United Kingdom |
| NICE | National Institute for Health and Care Excellence |
| IVM | In vitro maturation |
| PCOS | Polycystic ovarian syndrome |
| ART | Assisted reproductive technology |